{"id":144617,"date":"2022-08-23T01:23:25","date_gmt":"2022-08-23T06:23:25","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/08\/remedium-bio-closes-successful-2-3m-expanded-seed-raise"},"modified":"2022-08-23T01:23:25","modified_gmt":"2022-08-23T06:23:25","slug":"remedium-bio-closes-successful-2-3m-expanded-seed-raise","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/08\/remedium-bio-closes-successful-2-3m-expanded-seed-raise","title":{"rendered":"Remedium Bio closes successful $2.3m expanded seed raise"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/remedium-bio-closes-successful-2-3m-expanded-seed-raise2.jpg\"><\/a><\/p>\n<p>Remedium Bio has announced that it has closed more than $2.3m in its expanded seed round financing. Funding from the raise is being used to study Remedium\u2019s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss; this research is being conducted in collaboration with scientists from Tufts University School of Medicine who are engaged in researching rheumatic disorders.<\/p>\n<p>The financing was led by <a href=\"https:\/\/www.sherwood-ventures.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Sherwood Ventures<\/a> and included participation from, <a href=\"https:\/\/www.longevitytech.fund\/en\/home\" target=\"_blank\" rel=\"noreferrer noopener\">LongevityTech. Fund<\/a>, <a href=\"https:\/\/www.primomedicalgroup.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Primo Medical Group<\/a>, <a href=\"https:\/\/angelstarventures.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Angel Star Ventures<\/a>, <a href=\"https:\/\/apishealthangels.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Apis Health Angels<\/a>, <a href=\"https:\/\/microventures.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">MicroVentures<\/a>, and <a href=\"https:\/\/guindyangels.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Guindy Alumni Angels<\/a>.<\/p>\n<p><strong><em>Longevity. Technology: Remedium\u2019s pipeline includes therapeutic indications in osteoarthritis, diabetes, stroke and other large unmet clinical needs.<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Remedium Bio has announced that it has closed more than $2.3m in its expanded seed round financing. Funding from the raise is being used to study Remedium\u2019s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss; this research is being conducted in collaboration with scientists from Tufts University School of Medicine who [\u2026]<\/p>\n","protected":false},"author":556,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-144617","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/144617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=144617"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/144617\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=144617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=144617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=144617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}